Luoxin Pharmaceuticals Group Stock Co., Ltd. (SHE:002793)

SHE:002793 Revenue

Luoxin Pharmaceuticals Group Stock had revenue of 564.73M CNY in the quarter ending June 30, 2026, a decrease of -5.01%. This brings the company's total for the last twelve months to 2.34B, down -4.94% year-over-year. In the year 2025, Luoxin Pharmaceuticals Group Stock had annual revenue of 2.27B, down -14.12%. That makes Luoxin Pharmaceuticals Group Stock the 13,411th largest company in the world by revenue and 2,350th in China.

• Revenue (ttm): 2.34B
• Revenue Growth: -4.94%
• P/S Ratio: 2.00
• Revenue / Employee: 791.25K
• Employees: 2,962
• Market Cap: 4.69B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Industry 2.01B 88.4%
• Pharmaceutical Commercial 203.56M 9.0%
• Unallocated Other Business 59.09M 2.6%

By Geography

Chart

• East China 922.29M 40.6%
• North China 294.07M 12.9%
• Southwest Region 242.10M 10.6%
• Northeast China Region 212.46M 9.3%
• Central China 197.33M 8.7%
• Southern China 168.73M 7.4%
• Northwestern Region 124.16M 5.5%
• Other 112.33M 4.9%

Fiscal year ended Dec 31, 2025 See the full SHE:002793 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.27B	-373.91M	-14.12%
Dec 31, 2024	2.65B	283.50M	11.99%
Dec 31, 2023	2.36B	-1.22B	-34.11%
Jan 1, 2023	3.59B	-2.89B	-44.62%
Jan 1, 2022	6.48B	381.70M	6.26%

Data Source: S&P Global Market Intelligence Last updated: Aug 20, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error